ReviewMedComm2025
Cancer Stem Cells in Human Gastrointestinal and Hepatic Cancers.
Review in MedComm, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.MedScience · 2026Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal cancers, including gastric, hepatic, and colorectal cancers, represent a major public health problem globally. Although the 5-year survival rate of gastrointestinal tumors has been greatly improved due to the progress of diagnostic and therapeutic strategies, therapeutic resistance and distant metastasis remain the leading causes of cancer-related death in patients with gastrointestinal tumors. Cancer stem cells (CSCs) are a population of self-renewal cells with extremely strong carcinogenic potency, contributing to the progression, metastasis, and therapeutic resistance of gastrointestinal tumors. It is generally accepted that gastrointestinal CSCs have the characteristics of self-renewal, pluripotency, tumorigenicity, metastatic potential, and therapeutic resistance. Hence, understanding the behaviors of gastrointestinal CSCs is important for characterizing the stemness landscapes of gastrointestinal tumors and developing promising strategies for the treatment of gastrointestinal tumors. This review aims to discuss the basic characteristics of gastrointestinal CSCs, existing approaches to define and isolate CSCs, and canonical molecular pathways involved in the regulation of gastrointestinal CSCs. More importantly, potential strategies targeting gastrointestinal CSCs are proposed to overcome the limitations of current therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.